FDA head urges probe of agency’s dealings with Biogen, maker of controversial new Alzheimer’s drug – The Washington Post
Woodcock expressed tremendous confidence in the integrity of the staff and leadership involved in the approval and their commitment to unbiased and science-based decision-making. But she said an independent review was important to answer questions that…
